The global natural killer (NK) cell therapeutics market size is evaluated at USD 477.10 million in 2025 and is forecasted to hit around USD 9,997.65 million by 2034, growing at a CAGR of 40.22% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Natural Killer (NK) Cell Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Natural Killer (NK) Cell Therapeutics Market, by Therapeutic
8.1.1. NK Cell Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. NK Cell Directed Antibodies
8.1.2.1. Market Revenue and Forecast
9.1. Natural Killer (NK) Cell Therapeutics Market, by Approach
9.1.1. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
9.1.1.1. Market Revenue and Forecast
9.1.2. Bispecific Antibodies
9.1.2.1. Market Revenue and Forecast
10.1. Natural Killer (NK) Cell Therapeutics Market, by Application
10.1.1. Cancer
10.1.1.1. Market Revenue and Forecast
10.1.2. Immunoproliferative Disorders
10.1.2.1. Market Revenue and Forecast
10.1.3. Acute Infectious Diseases
10.1.3.1. Market Revenue and Forecast
10.1.4. Gastrointestinal Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Natural Killer (NK) Cell Therapeutics Market, by End-user
11.1.1. Research & Academic Institutes
11.1.1.1. Market Revenue and Forecast
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast
11.1.3. Specialty Clinics
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutic
12.1.2. Market Revenue and Forecast, by Approach
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by End-user
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutic
12.1.5.2. Market Revenue and Forecast, by Approach
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by End-user
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutic
12.1.6.2. Market Revenue and Forecast, by Approach
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by End-user
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutic
12.2.2. Market Revenue and Forecast, by Approach
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by End-user
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutic
12.2.5.2. Market Revenue and Forecast, by Approach
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by End-user
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutic
12.2.6.2. Market Revenue and Forecast, by Approach
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by End-user
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutic
12.2.7.2. Market Revenue and Forecast, by Approach
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by End-user
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutic
12.2.8.2. Market Revenue and Forecast, by Approach
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by End-user
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutic
12.3.2. Market Revenue and Forecast, by Approach
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by End-user
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutic
12.3.5.2. Market Revenue and Forecast, by Approach
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by End-user
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutic
12.3.6.2. Market Revenue and Forecast, by Approach
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by End-user
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutic
12.3.7.2. Market Revenue and Forecast, by Approach
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by End-user
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutic
12.3.8.2. Market Revenue and Forecast, by Approach
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by End-user
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutic
12.4.2. Market Revenue and Forecast, by Approach
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by End-user
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutic
12.4.5.2. Market Revenue and Forecast, by Approach
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by End-user
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutic
12.4.6.2. Market Revenue and Forecast, by Approach
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by End-user
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutic
12.4.7.2. Market Revenue and Forecast, by Approach
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by End-user
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutic
12.4.8.2. Market Revenue and Forecast, by Approach
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by End-user
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutic
12.5.2. Market Revenue and Forecast, by Approach
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by End-user
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutic
12.5.5.2. Market Revenue and Forecast, by Approach
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by End-user
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutic
12.5.6.2. Market Revenue and Forecast, by Approach
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by End-user
13.1. Bristol-Myers Squibb Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Cytovia Therapeutics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Glycostem
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ImmunityBio, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Biohaven Pharmaceuticals
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Fate Therapeutics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. EMERcell
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck KGaA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Phio Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Sanofi
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample